Department of Obstetrics and Gynecology, University of Saarland, 66424, Homburg, Saar, Germany.
Department of Otorhinolaryngology, Head and Neck Surgery, University of Saarland, 66424, Homburg, Saar, Germany.
Arch Gynecol Obstet. 2019 May;299(5):1405-1413. doi: 10.1007/s00404-019-05081-4. Epub 2019 Feb 12.
In previous studies, we have shown that SEC62 has an essential function in cell migration, epithelial-to-mesenchymal transition, and endoplasmic reticulum stress tolerance of cancer cells. SEC62 expression correlated with distant and lymph node metastasis and poor outcome in different cancer entities. In this initial study, we investigated SEC62 expression and its possible role as a prognostic and predictive biomarker in breast cancer (BC).
Formalin-fixed, paraffin-embedded tissue samples of 53 BC patients were analyzed by immunohistochemistry. The immunoreactive score (IRS) according to Remmele and Stegner was evaluated and correlated with clinico-pathological findings and overall survival (OS).
We found increased SEC62 protein levels in tumor tissue compared to tumor-free tissue samples from the same patients. Tumors with high SEC62 expression (IRS > 8), or containing isolated cells with high SEC62 staining intensity, independent of the IRS, had more frequently distant metastases (48.4% vs. 18.2%; p = 0.024 and 47.4 vs. 6.7%; p = 0.005, respectively). Overall survival was significantly worse in BC patients with high SEC62 expression (SEC62 IRS > 8) (54.8% vs. 81.8%; p = 0.011) and in cases with isolated high-intensity SEC62 staining cells independently of SEC62 IRS (55.3% vs 93.3%; p = 0.024).
We are the first to describe the SEC62 expression and its correlation to clinicopathological parameters in mammary carcinoma. Our results suggest that SEC62 expression may serve as a prognostic marker for patients with invasive ductal breast cancer.
在之前的研究中，我们已经表明 SEC62 在癌细胞的细胞迁移、上皮-间充质转化和内质网应激耐受中具有重要功能。SEC62 的表达与不同癌症实体的远处和淋巴结转移以及不良预后相关。在这项初步研究中，我们研究了 SEC62 表达及其作为乳腺癌（BC）预后和预测生物标志物的可能作用。
对 53 例 BC 患者的福尔马林固定、石蜡包埋组织样本进行免疫组织化学分析。根据 Remmele 和 Stegner 的免疫反应评分（IRS）进行评估，并与临床病理发现和总生存（OS）相关联。
我们发现与来自同一患者的无肿瘤组织样本相比，肿瘤组织中 SEC62 蛋白水平升高。SEC62 表达高（IRS>8）的肿瘤或含有独立的高 SEC62 染色强度的细胞的肿瘤，更频繁地发生远处转移（48.4%比 18.2%；p=0.024 和 47.4 比 6.7%；p=0.005）。SEC62 表达高（IRS>8）的 BC 患者的总生存率明显更差（54.8%比 81.8%；p=0.011），并且独立于 SEC62 IRS 的情况下存在孤立的高 SEC62 染色细胞的病例（55.3%比 93.3%；p=0.024）。
我们是第一个描述 SEC62 在乳腺腺癌中的表达及其与临床病理参数的相关性的人。我们的结果表明，SEC62 表达可能作为浸润性导管乳腺癌患者的预后标志物。
